Q3 2025 EPS Estimates for Thermo Fisher Scientific Inc. (NYSE:TMO) Reduced by Analyst

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Thermo Fisher Scientific in a research report issued to clients and investors on Friday, September 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $5.91 for the quarter, down from their previous estimate of $6.00. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $21.72 per share.

TMO has been the subject of several other reports. Robert W. Baird increased their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an "outperform" rating in a report on Thursday, July 25th. Bank of America raised their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a report on Monday. Stifel Nicolaus increased their price target on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an "outperform" rating in a research report on Thursday, July 25th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $632.89.

Thermo Fisher Scientific Trading Up 0.5 %

Thermo Fisher Scientific stock traded up $2.98 during mid-day trading on Monday, hitting $614.15. The company's stock had a trading volume of 1,182,668 shares, compared to its average volume of 1,498,353. The business has a 50 day moving average price of $592.10 and a 200-day moving average price of $580.22. Thermo Fisher Scientific has a 12 month low of $415.60 and a 12 month high of $627.88. The stock has a market cap of $234.43 billion, a price-to-earnings ratio of 39.20, a price-to-earnings-growth ratio of 2.86 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts' consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analysts' expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period last year, the firm posted $5.15 EPS.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific's payout ratio is currently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares of the company's stock, valued at $10,747,403.95. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,084 shares of company stock valued at $14,094,292. Corporate insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Capital World Investors lifted its stake in Thermo Fisher Scientific by 10.0% during the 1st quarter. Capital World Investors now owns 13,493,852 shares of the medical research company's stock valued at $7,842,762,000 after acquiring an additional 1,231,059 shares during the period. Swedbank AB purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $705,636,000. Veritas Asset Management LLP lifted its position in Thermo Fisher Scientific by 70.1% during the fourth quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company's stock valued at $898,175,000 after purchasing an additional 697,383 shares during the period. Winslow Capital Management LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $333,786,000. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Thermo Fisher Scientific by 32.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock valued at $1,372,157,000 after buying an additional 604,895 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.